Pfizer and KineMed Inc. have renewed a non-exclusive research collaboration for the advancement of new approaches in metabolic disease, namely Type II diabetes. The collaboration employs KineMed’s proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.
“We are very pleased to announce the extension of this ongoing partnership in an important area of medicine that affects so many Americans. Our translational biomarker platform targets the metabolic processes and pathways that play a pathogenic role in disorders such as diabetes,” said Marc Hellerstein, M.D., Ph.D., president, chief science officer and co-founder at KineMed. “This platform has been useful in accelerating advancement and de-risking compounds in Type II diabetes. We look forward to continuing our work with Pfizer on their compounds in preclinical and clinical trials.”
KineMed, Pfizer Extend Diabetes Pact
Published June 4, 2014
Related Breaking News
Related Online Exclusives